Last reviewed · How we verify
Lurasidone Oral Capsule
Lurasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT7 receptors to reduce psychotic symptoms and mood disturbances.
Lurasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT7 receptors to reduce psychotic symptoms and mood disturbances. Used for Schizophrenia, Bipolar I disorder depression, Major depressive disorder (adjunctive treatment).
At a glance
| Generic name | Lurasidone Oral Capsule |
|---|---|
| Also known as | Lurasidone Fixed Dose Combination, Latuda®, Latuda |
| Sponsor | NeuroRx, Inc. |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, Serotonin 5-HT7 receptor, Serotonin 5-HT1A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | Phase 3 |
Mechanism of action
Lurasidone acts as an antagonist at dopamine D2 receptors and serotonin 5-HT7 receptors, with additional activity at 5-HT1A receptors. This multi-target receptor profile is characteristic of atypical antipsychotics and helps modulate both dopaminergic and serotonergic neurotransmission implicated in psychosis and mood disorders. The oral capsule formulation allows for systemic delivery to achieve therapeutic CNS concentrations.
Approved indications
- Schizophrenia
- Bipolar I disorder depression
- Major depressive disorder (adjunctive treatment)
Common side effects
- Akathisia
- Somnolence
- Parkinsonism
- Nausea
- Restlessness
- Tremor
Key clinical trials
- A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication (PHASE2)
- NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation (PHASE3)
- NRX101 Glx Biomarker Validation Study (PHASE2, PHASE3)
- Sequential Therapy for the Treatment of Severe Bipolar Depression. (PHASE2)
- NMDA Antagonists in Bipolar Depression (PHASE4)
- Lithium Drug-Drug Interaction Study With Lurasidone HCl (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lurasidone Oral Capsule CI brief — competitive landscape report
- Lurasidone Oral Capsule updates RSS · CI watch RSS
- NeuroRx, Inc. portfolio CI